The present invention is directed to compounds of Formula (I) or pharmaceutically
acceptable salts thereof; wherein X is hydrogen, Cl, Br, I, NO2, NR3R4
or -L-Ch; Y is hydrogen, -CH2OR5, -CH2NCH3R1,
NO2, NR3R4 or -L-Ch; Y is hydrogen, -CH2OH5,
-CH2NCH3R1, NO2, NR3R4
OR -L-Ch; provided that at least one of the Y or Y is -CH2NCH3R1;
Z is S, O, NR6 CR7R8, C(O) or -C(CR7R8)-;
A is hydrogen, Cl, I, Br or -L-Ch; R1 is hydrogen, C1-C5
alkyl, C3-C8 cycloalkyl C1-5 alkylcarbonyl, (C3-C8
cycloalkyl) carbonyl, pnenyl, benzyl, naphthyl, naphthylmethyl or L-Ch; R2
is hydrogen or methyl; and R3-R8 are as defined herein.
Radiolabeled compounds of the invention are useful as selective serotonin transporter
(SERT) imaging agents for single photon emission tomography (SPECT). As such the
compounds are useful for studying the underlying pharmacology and interaction of
specific serotinin reuptake site inhibitors (SSRI), commonly used antidepressants,
at the SERT sites in the human brain. Certain compounds of the invention, including
IDAM (5-iodo-2[[2-2-[(dimethylamino)methyl]phenyl]thio]benzylalcohol) display affinity
to SERT sites and show more high selectively for SERT over NET and DAT.
